Empagliflozin prevents neointima formation by impairing smooth muscle cell proliferation and accelerating endothelial regeneration.

Front Cardiovasc Med · 2022 · PMC9396257 · PMID 36017090

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

However, the impact of empagliflozin on non-diabetic EC function did not reach statistical significance, neither in vitro nor in vivo .

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.